ClinicalTrials.gg
RecruitingNCT04640532Updated May 9, 2022

KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF

A Phase 1/2 interventional study of KRT-232 and TL-895 in Myelofibrosis, Post-PV MF and Post-ET Myelofibrosis, sponsored by Kartos Therapeutics, Inc.. Recruiting at 37 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-05-09.

Sponsored by Kartos Therapeutics, Inc. (part of Ipsen) · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2022, 4 years 6 months ago, but the record still lists the study as recruiting.
  • Started Nov 2020; still recruiting 6 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
116
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 454 studies in Primary Myelofibrosis with a site in United States — 70 open to participants now, 105 under way, 12 of them phase 3. Primary Myelofibrosis · United States.

Planned enrollment
77th of 388
116 · median 40
Started
2020
with 14 others
Phase 1/2
50 of 454
11 open now
Primary completion
2022-05
later than 4 of 104 live
Registered
372nd of 454
by date

Among the 454 studies in Primary Myelofibrosis with a site in United States, this one is the 77th largest by planned enrollment of the 388 interventional ones that give a count, is one of 15 that started in 2020, is one of 50 in phase 1/2, reaches primary completion later than 4 of the 104 other live ones, and was the 372nd registered.

Primary Myelofibrosis

628 studies on the registry are indexed under Primary Myelofibrosis; 126 are open to participants now.

Browse Primary Myelofibrosis studies →

Open to participants now

70 of the 454 studies in Primary Myelofibrosis with a site in United States are open now. Recruiting first, the newest first:

65 more — sign in →

All 70 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 11 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 454 studies in Primary Myelofibrosis with a site in United States, or all of them as a file.
02

Study summary

This study evaluates KRT-232 in Combination With TL-895 for the Treatment of Relapsed or Refractory Myelofibrosis and KRT-232 for the Treatment of JAK Inhibitor Intolerant Myelofibrosis.

Read the detailed description

Cohorts 1 and 2 will undergo dose finding and dose expansion. Eligible patients will be randomly assigned to an open cohort, either Cohort 1 or Cohort 2. Cohort 3 will be conducted as a dose expansion, independent of Cohorts 1 and 2.

Cohort 1 will follow a 3+3 dose escalation design to determine the maximum tolerated dose (MTD)/maximum administered dose (MAD) and recommended Phase 2 dose (RP2D) of TL-895 administered QD in combination with KRT-232. A Safety Review Committee (SRC) will review the safety data during the dose escalation to decide on dose escalation and/or exploration of intermediate doses.

Cohort 2 will follow a 3+3 dose escalation design to determine the MTD/MAD and recommended RP2D of TL-895 administered BID in combination with KRT-232. An SRC will review the safety data during the dose escalation to decide on dose escalation and/or exploration of intermediate doses.

Cohort 3 will be conducted a 2-stage design. In stage 1, enrollment will continue until 15 evaluable patients have been enrolled. An SRC will review the data during the study and if there are ≥4 responders based on the futility criteria and safety data from Stage 1, Cohort 3 expansion will commence. If there are ≤3 patients responding to therapy, Cohort 3 will be terminated. Once expansion criteria have been met, Cohort 3 will be expanded to a total of 46 evaluable patients for Stage 2 analyses.

03

Conditions studied

  • Myelofibrosis
  • Post-PV MF
  • Post-ET Myelofibrosis
  • Primary Myelofibrosis

Browse trials for

Keywords

  • Relapsed/Refractory Myelofibrosis
  • Janus associated Kinase Inhibitor-Intolerant Myelofibrosis
  • MDM2
  • navtemadlin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of primary MF, post-PV MF, or post-ET MF, (WHO 2016)
  • ≤ 2
  • Cohort 1 and Cohort 2: R/R following JAK inhibitor treatment
  • Cohort 3: patients who are intolerant to JAK inhibitor treatment

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with MDM2 inhibitors or p53-directed therapies
  • Prior treatment with a BCR-ABL, phosphoinositide 3-kinase (PI3k), mammalian target of rapamycin (mTOR), bromodomain and extraterminal domain (BET), histone deacetylase (HDAC), or spleen tyrosine kinase (Syk) inhibitor
  • Prior splenectomy
  • Splenic irradiation within 3 months prior to the first dose of study treatment
  • thrombosis within 3 months of screening
  • Grade 2 or higher prolongation
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
116 participants (estimated)

Study arms

  • Experimental
    Cohort 1 (R/R MF), Dose Level 1

    TL-895 at 200 mg once a day (QD) continuously starting on Cycle 1 Day 1 in a 28-day cycle. KRT-232 240mg will be administered orally, once daily (QD), on days 1-7 in a 28-day cycle starting on Cycle 2 Day 1.

    Drug: KRT-232 · Drug: TL-895

  • Experimental
    Cohort 1 (R/R MF), Dose Level 2

    TL-895 at 300 mg once a day (QD) continuously starting on Cycle 1 Day 1 in a 28-day cycle. KRT-232 at 240mg will be administered orally, once daily (QD), on days 1-7 in a 28-day cycle starting on Cycle 2 Day 1.

    Drug: KRT-232 · Drug: TL-895

  • Experimental
    Cohort 2 (R/R MF), Dose Level 1

    TL-895 at 100 mg twice a day (BID) continuously starting on Cycle 1 Day 1 in a 28-day cycle. KRT-232 at 240mg will be administered orally, once daily (QD), on days 1-7 in a 28-day cycle starting on Cycle 2 Day 1.

    Drug: KRT-232 · Drug: TL-895

  • Experimental
    Cohort 2 (R/R MF), Dose Level 2

    TL-895 at 150 mg twice a day (BID) continuously starting on Cycle 1 Day 1 in a 28-day cycle. KRT-232 at 240mg will be administered orally, once daily (QD), on days 1-7 in a 28-day cycle starting on Cycle 2 Day 1.

    Drug: KRT-232 · Drug: TL-895

  • Experimental
    Cohort 3 (JAKi Intolerant MF)

    KRT-232 at 240mg will be administered orally, once daily (QD), on days 1-7 in a 28-day cycle.

    Drug: KRT-232

Interventions

06

What researchers measure

Primary outcomes

  1. Phase 1b - The MTD/MAD and RP2D of TL-895 in combination with KRT-232 in patients with R/R MF (Cohort 1 and Cohort 2)

    DLTs will be used to establish the MTD. RP2D will be determined by the SRC based on safety data from the combination of TL-895 and KRT-232.

    Time frame: 56 Days

  2. Phase 2 - Spleen response rate for each cohort

    A reduction in spleen volume as assessed by MRI (or CT) ≥ 35% from baseline at Week 24

    Time frame: 24 Weeks

Secondary outcomes

  1. Total Symptom Score (TSS)

    The change in TSS based Myelofibrosis Symptom Assessment Form version 4.0 (MFSAF v4.0)

    Time frame: 24 Weeks

07

Study locations

37 of 37 sites recruiting
  • University of Alabama at Birmingham School of Medicine, Division of Hematology and Oncology
    Birmingham, Alabama 35233, United States
    Recruiting
  • The Oncology Institute of Hope
    Whittier, California 90603, United States
    Recruiting
  • Lake City Cancer Center
    Lake City, Florida 32024, United States
    Recruiting
  • Carle Cancer Center
    Urbana, Illinois 61801, United States
    Recruiting
  • Columbia University Medical Center
    Fort Lee, New Jersey 07024, United States
    Recruiting
  • Memorial Sloan Kettering Cancer Center (MSKCC)
    New York, New York 10065, United States
    Recruiting
  • LKH Hochsteiermark
    Leoben, 8700, Austria
    Recruiting
  • Meduni Wien, Univ. Klinik für Innere Medizin I
    Wien, 1090, Austria
    Recruiting
  • University Multiprofile Hospital for Active Treatment Dr. Georgi Stranski, Pleven
    Pleven, 5800, Bulgaria
    Recruiting
  • University Multiprofile Hospital for Active Treatment Dr. Georgi Plovdiv
    Plovdiv, 4002, Bulgaria
    Recruiting
  • Hematology Clinic Specialized Hospital for Active Treatment of Hematological Diseases, Sofia
    Sofia, 1756, Bulgaria
    Recruiting
  • Chu Amiens Picardie Site Sud
    Amiens, 80054, France
    Recruiting
  • CHU de Limoges Service Hématologie Clinique et Thérapie Cellulaire
    Limoges, 87042, France
    Recruiting
  • CHU Nantes - Hôtel Dieu
    Nantes, 44093, France
    Recruiting
  • CHU de Nice Hospital
    Nice, 06200, France
    Recruiting
  • Hôpital Saint Louis
    Paris, 75475, France
    Recruiting
  • Centre Hospitalier Lyon Sud
    Pierre-Bénite, 63310, France
    Recruiting
  • University Hospital Halle (Saale), Department of Internal Medicine IV - Hematology and Oncology
    Halle, 06120, Germany
    Recruiting
  • University Hospital Marburg, Department of Hematology, Oncology and Immunology
    Marburg, 35043, Germany
    Recruiting
  • Moritz Kaposi General Hospital, Department of Hematology
    Kaposvár, H-7400, Hungary
    Recruiting
  • Szabolcs-Szatmar-Bereg County Hospitals and University Teaching Hospital, Department of Hematology
    Nyíregyháza, H-4400, Hungary
    Recruiting
  • Medical Center of the University of Pecs, 1st Department of Internal Medicine, Division of Hematology
    Pécs, H-7624, Hungary
    Recruiting
  • Fejer County St. Gyorgy University Teaching Hospital, Department of Internal Medicine III, Hematology
    Székesfehérvár, H-8000, Hungary
    Recruiting
  • Polyclinic S. Orsola-Malpighi
    Bologna, 40138, Italy
    Recruiting
  • ASST Spedali Civili di Brescia
    Brescia, 25123, Italy
    Recruiting
  • Careggi University Hospital
    Florence, 50134, Italy
    Recruiting
  • Hospital Casa Sollievo della Sofferenza, Department of Oncology and Hematology, Division of Hematology
    Foggia, 71013, Italy
    Recruiting
  • Hospital of Ravenna, Operative Unit of Hematology
    Ravenna, 48121, Italy
    Recruiting
  • Jan Biziel University Hospital #2 in Bydgoszcz, Department of Hematology
    Bydgoszcz, 85-168, Poland
    Recruiting
  • Pratia Onkologia Katowice
    Katowice, 40-519, Poland
    Recruiting
  • Frederic Chopin Provincial Teaching Hospital No. 1 in Rzeszow, Department of Hematology
    Rzeszów, 35-055, Poland
    Recruiting
  • Slupsk Provincial Specialist Hospital n.a. Janusz Korczak, Department of Hematology
    Słupsk, 76-200, Poland
    Recruiting
  • Nasz Lekarz Medical Outpatient Clinics Slawomir Jeka
    Toruń, 87-100, Poland
    Recruiting
  • Clinical Center of Serbia
    Belgrade, 11000, Serbia
    Recruiting
  • Clinical Center of Vojvodina
    Novi Sad, 21000, Serbia
    Recruiting
  • Hematologia Clínica
    Barcelona, 08003, Spain
    Recruiting
  • University Clinical Hospital of Salamanca, Department of Hematology
    Salamanca, 37007, Spain
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2020 (actual). Primary completion is estimated for May 2022, 17 months after the start.

Of 27 phase 1/2 interventional studies under Primary Myelofibrosis, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 52 and three quarters within 125. This study's planned 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2020
First posted
Nov 23, 2020
StartActual
Nov 17, 2020
Primary completionEst.
May 11, 2022
CompletionEst.
Jul 24, 2025
Last update
May 9, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 9, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04640532
Collaborators
Telios Pharma, Inc.
Responsible party
Sponsor
First posted
Nov 23, 2020
Start date
Nov 17, 2020
Primary completion
May 11, 2022 (estimated)
Completion
Jul 24, 2025 (estimated)
Last update
May 9, 2022

Study contacts

John Mei
Contact
jmei@kartosthera.com
650-542-0136
Irene Dea
Contact
idea@kartosthera.com
(650) 839-7341

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Navtemadlin

Start the discussion